FDA Details Draft Framework for Speeding Access to Ultra-Rare Disease Treatments
- February 27, 2026
The Food and Drug Administration (FDA) unveiled February 23 a new draft framework aimed at accelerating approval of targeted therapies treating conditions so rare that randomized controlled trials may not be feasible.
ARTICLE TAGS
You must be logged in to access this content.